Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care,...
Kailera Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care,...